Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

676 recalls · Class II, newest first

Class II · Moderate risk

Glycopyrrolate

Lack of Assurance of Sterility: Leaking/damaged syringes.

Ongoing Sterility / contamination Denver Solutions, LLC DBA Leiters Health NDC 71449-104-11 D-0370-2025
Class II · Moderate risk

Unisom

CGMP Deviations; detection of Nitrosamine Drug Substance-Related Impurities (NDSRI), N-nitroso-desmethyl-diphenhydramine (n-dph), above the FDA Recommended Intake Limit

Ongoing Nitrosamine impurity Chattem Inc D-0362-2025
Class II · Moderate risk

Duloxetine Delayed-Release Capsules

CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

Ongoing Nitrosamine impurity Breckenridge Pharmaceutical, Inc. NDC 51991-747-10 D-0308-2025
Class II · Moderate risk

Voriconazole Tablets

cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.

Terminated cGMP deviation Amerisource Health Services LLC NDC 60687-294-21 D-0307-2025
Class II · Moderate risk

Venlafaxine Tablets

Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.

Completed Particulate / foreign matter Zydus Pharmaceuticals (USA) Inc NDC 68382-021-01 D-0310-2025

Recalls by year